

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5880322

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIONTECH AG	03/21/2017
RECEIVING PARTY DATA	
Name:	BIONTECH RNA PHARMACEUTICALS GMBH
Street Address:	AN DER GOLDGRUBE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16578601
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172485000
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2013237-0047
NAME OF SUBMITTER:	JANET M. TSE, SCD
SIGNATURE:	/Janet M. Tse/
DATE SIGNED:	12/20/2019
Total Attachments: 3	
source=Assignment (Biontech AG to Biontech RNA Pharmaceuticals GMBH)#page2.tif	
source=Assignment (Biontech AG to Biontech RNA Pharmaceuticals GMBH)#page3.tif	
source=Assignment (Biontech AG to Biontech RNA Pharmaceuticals GMBH)#page4.tif	

CORPORATION TO CORPORATION ASSIGNMENT

This Assignment is by:

Assignor: BioNTech AG
Address: An der Goldgrube 12, 55131 Mainz, GERMANY
A juristic entity duly organized under and pursuant to the laws of: Germany

(referred to in this Assignment as "Assignor"), which is an owner, by assignment, of the U.S. patent applications identified in the attached Appendix A:

This Assignment is to:

Assignee: BIONTECH RNA PHARMACEUTICALS GMBH
Address: An der Goldgrube 12, 55131 Mainz, GERMANY
A juristic entity duly organized under and pursuant to the laws of: Germany

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,


1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the patent applications listed in the attached Appendix A, the inventions therein, any and all provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of the entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor was the sole and lawful owner of the entire right, title and interest in and to said inventions and said application for letters patent, and that the same were unencumbered and that Assignor sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to said inventions and said application for letters patent.
3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any provisional, non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof; or any substitution of any such application; (c) any letters patent or patents for said inventions in any country or jurisdiction, including without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding. To be clear, for purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the letters patent of the United States to Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.


5. "I hereby grant Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known."

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: March 21st, 2017 Signature: 
Name: Sean Martz
Title: Managing Director
Company: BioNTech AG

ASSIGNEE:

Date: March 20th, 2017 Signature: 
Name: Dr. Siek Pething
Title: Managing Director
Company: BIONTECH RNA PHARMACEUTICALS GMBH

APPENDIX A

Attorney Docket No. (Client Ref.)	Application No.	Filing Date	Title	Inventors
146392039000 (674-75 PCTUS)	14/119,348	5/23/2012 (Int'l)	INDIVIDUALIZED VACCINES FOR CANCER	Ugur SAHIN et al.
146392039100 (674-84 PCTUS)	14/388,192	3/25/2013 (Int'l)	RNA FORMULATION FOR IMMUNOTHERAPY	Ugur SAHIN et al.
146392039300 (674-99 PCTUS)	14/787,110	5/7/2014 (Int'l)	PREDICTING IMMUNOGENICITY OF T CELL EPITOPES	Ugur SAHIN et al.